Brief: UCB Announces A Study Evaluating Bimzelx Versus Skyrizi In Psoriatic Arthritis

UCB SA

30/09/2024 06:08

Sept 30 (Reuters) - Ucb SA  UCB.BR :
    * ANNOUNCES A HEAD-TO-HEAD STUDY EVALUATING
BIMZELX ® ▼(BIMEKIZUMAB) VERSUS SKYRIZI® (RISANKIZUMAB) IN
ACTIVE PSORIATIC ARTHRITIS
    * STUDY UNDERSCORES UCB'S BELIEF IN BIMEKIZUMAB WITH
TOP-LINE
RESULTS EXPECTED IN 2026

Source text: https://shorturl.at/w5kKi
Further company coverage:  UCB.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))